

Male												
	Treatment Groups (mg/kg)											
	50 <sup>a, 2</sup>	200 <sup>b, 3</sup>		200 <sup>c, 4</sup>		200 <sup>d, 2</sup>		200 <sup>a, 4</sup>	200 <sup>a, 2</sup>	200 <sup>a, 3</sup>	400 <sup>a, 2</sup>	6 IV <sup>a, 1</sup>
	Plasma											
Beta (min <sup>-1</sup> )	0.0041							0.0030	0.0043	0.0030	0.0023	0.0038
t <sub>1/2(Beta)</sub> (minute)	168							230	161	230	303	185
k <sub>01</sub> (min <sup>-1</sup> )		0.102 ± 0.12	0.0950 ± 0.11	0.100 ± 0.13								
k <sub>10</sub> (min <sup>-1</sup> )		0.0108 ± 0.0036	0.0105 ± 0.0033	0.0110 ± 0.0035								
Cl (L/min/kg)		0.0430										
Cl <sub>1(F)</sub> (L/min/kg)	1.93							1.83	2.60	2.61	2.01	
V <sub>1</sub> (L/kg)	470	2.74 ± 0.68	2.53 ± 0.60	2.90 ± 0.68	607	602	867	880	11.5			
MRT (minute)	209							236	237	244	542	165
AUC <sub>inf</sub> (ug*min/L)	20789							92827	63848	76657	172514	156914
F (fraction)	0.0222							0.0235	0.0165	0.0165	0.0214	

Female												
	Treatment Groups (mg/kg)											
	50 <sup>a, 2</sup>	200 <sup>e, 3</sup>		200 <sup>f, 4</sup>		200 <sup>g, 2</sup>		200 <sup>a, 4</sup>	200 <sup>a, 2</sup>	200 <sup>a, 3</sup>	400 <sup>a, 2</sup>	6 IV <sup>a, 1</sup>
	Plasma											
Beta (min <sup>-1</sup> )	0.0028					0.0042	0.0061	0.0051	0.0073	0.0059		
t <sub>1/2(Beta)</sub> (minute)	246					164	113	136	94.4	118		
k <sub>01</sub> (min <sup>-1</sup> )		0.119 ± 0.14	0.107 ± 0.11	0.0957 ± 0.16								
k <sub>10</sub> (min <sup>-1</sup> )		0.0103 ± 0.0030	0.0107 ± 0.0030	0.0110 ± 0.0033								
Cl (L/min/kg)											0.0544	
Cl <sub>1(F)</sub> (L/min/kg)	4.81					2.30	7.96	2.44	6.48			
V <sub>1</sub> (L/kg)	1710	4.24 ± 0.90	3.84 ± 0.79	3.76 ± 0.82	543	1295	479	883	9.25			
MRT (minute)	327					182	178	176	120	128		
AUC <sub>inf</sub> (ug*min/L)	8480					72767	21100	82045	53694	123068		
F (fraction)	0.0113					0.0237	0.00683	0.0223	0.00839			

**Experiment Number:** S0555

**Route:** Dermal, IV

**Species/Strain:** Rat/F344

**Toxicokinetics Data Summary**

**Test Compound:** DL-Camphor

**CAS Number:** 21368-68-3

**Date Report Requested:** 11/09/2016

**Time Report Requested:** 14:02:45

**Lab:** Research Triangle Institute

**LEGEND**

---

Data are displayed as mean  $\pm$  SEM

**MODELING METHOD & BEST FIT MODEL**

<sup>a</sup> WinNonlin, Version 1 .0 (Scientific Consulting Inc ., 1995); non-compartmental analysis (WinNonlin Models 200 or 201).

<sup>b</sup> WinNonlin, Version 1 .0 (Scientific Consulting Inc ., 1995); Compartmental models were written to simultaneously solve iv and dermal data sets (WinNonlin) with 1/YHAT weighting, where YHAT is the predicted plasma d,l-camphor concentration at a given time. O and AD simultaneously solved iv and single administration mid dose dermal unprotected, male rats.

<sup>c</sup> WinNonlin, Version 1 .0 (Scientific Consulting Inc ., 1995); Compartmental models were written to simultaneously solve iv and dermal data sets (WinNonlin) with 1/YHAT weighting, where YHAT is the predicted plasma d,l-camphor concentration at a given time. O and AG simultaneously solved iv and repeated administration mid dose dermal unprotected, male rats.

<sup>d</sup> WinNonlin, Version 1 .0 (Scientific Consulting Inc ., 1995); Compartmental models were written to simultaneously solve iv and dermal data sets (WinNonlin) with 1/YHAT weighting, where YHAT is the predicted plasma d,l-camphor concentration at a given time. O and Y simultaneously solved iv and single administration mid dose dermal protected, male rats.

<sup>e</sup> WinNonlin, Version 1 .0 (Scientific Consulting Inc ., 1995); Compartmental models were written to simultaneously solve iv and dermal data sets (WinNonlin) with 1/YHAT weighting, where YHAT is the predicted plasma d,l-camphor concentration at a given time). P and AE simultaneously solved iv and single administration mid dose dermal unprotected, female rats.

<sup>f</sup> WinNonlin, Version 1 .0 (Scientific Consulting Inc ., 1995); Compartmental models were written to simultaneously solve iv and dermal data sets (WinNonlin) with 1/YHAT weighting, where YHAT is the predicted plasma d,l-camphor concentration at a given time. P and AH simultaneously solved iv and repeated administration mid dose dermal unprotected, female rats.

<sup>g</sup> WinNonlin, Version 1 .0 (Scientific Consulting Inc ., 1995); Compartmental models were written to simultaneously solve iv and dermal data sets (WinNonlin) with 1/YHAT weighting, where YHAT is the predicted plasma d,l-camphor concentration at a given time. P and Z simultaneously solved iv and single administration mid dose dermal protected, female rats.

**ANALYTE**

DL-Camphor

**ROUTE & DOSE FREQUENCY**

<sup>1</sup> Intravenous, 1 per study

<sup>2</sup> Dermal Protected, 1 per study

<sup>3</sup> Dermal Unprotected, 1 per study

<sup>4</sup> Dermal Unprotected, Repeated dose, 7 per study

**TK PARAMETERS**

Beta = Hybrid rate constant of the beta phase

$t_{1/2}(\text{beta})$  = Half-life for the beta phase

$k_{01}$  = Absorption rate constant,  $k_a$

$k_{10}$  = Elimination rate constant from the central compartment also  $k_e$  or  $k_{elim}$

Cl = Clearance, includes total clearance

$Cl_{1(F)}$  = Apparent clearance of the central compartment, also  $Cl(F)$  for gavage groups in non-compartmental model

$V_1$  = Volume of distribution of the central compartment, includes  $V_d$  and  $V_{volume}$  of distribution,  $V_z$  apparent volume of distribution NCA,  $V_{app}$  apparent volume of distribution for intravenous studies

**Experiment Number:** S0555

**Route:** Dermal, IV

**Species/Strain:** Rat/F344

**Toxicokinetics Data Summary**

**Test Compound:** DL-Camphor

**CAS Number:** 21368-68-3

**Date Report Requested:** 11/09/2016

**Time Report Requested:** 14:02:45

**Lab:** Research Triangle Institute

LEGEND

---

TK PARAMETERS

MRT = Mean residence time

AUC<sub>inf</sub> = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity

F = Bioavailability, absolute bioavailability

**\*\* END OF REPORT \*\***